Open Access Open Access  Restricted Access Subscription Access

Mechanism of Anti-Cholinesterases and Medical Applications of Alzheimers Disease as Well as Myasthenia Gravis

Muralinath . E, Vaikunta Rao .V, Manjari .P, Sravani Pragna . K, Kalyan . C, Vinayasree . C, Guru Prasad .M, Venkat Naveen . A, Sravani . K

Abstract


Anti-cholinesterase plays a major role especially in neuro muscular disorders. These substances target the cholinesterase enzymes specifically acetyl cholinesterase (ACh E) to regulate the levels of acetyl choline, a neuro transmitter responsible for nerve signal transmission. Cholinesterase enzymes essentially ACh E and butyryl cholinesterase ( BuCH E) are responsible for breaking down acetyl choline after it has transmitted a nerve signal. Anti-cholinesterases perform their actions by stopping the activity of the enzyme acetyl cholinesterase. Acetyl cholinesterase is essential for breaking down the neurotransmitter acetyl choline particularly in the synaptic cleft, the gap between nerve cells. Medications such as donepezil, galantamine and rivastigmine inhibit ACh E as well as BuCH E and enhance cognitive function. Myasthenia gravis is an auto immune disorder that leads to the occurrence of muscle weakness and fatigue. Anti-cholinesterases especially pyridostigmine enhance muscle strength by prolonging acetylcholines action particularly at neuro muscular junctions. It is finally concluded that anti-cholinesterases are helpful in treating neuro muscular diseases by targeting cholinesterase enzymes and mofdulating acetyl choline levels.


Full Text:

PDF

References


Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013). Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology, 11(3), 315-335.

Ma, S. L., Tang, N. L. S., Wat, K. H. Y., Tang, J. H. Y., Lau, K. H., Law, C. B., ... & Lam, L. C. W. (2019). Effect of CYP2D6 and CYP3A4 genotypes on the efficacy of cholinesterase inhibitors in Southern Chinese patients with Alzheimer’s disease. American Journal of Alzheimer's Disease & Other Dementias®, 34(5), 302-307.

Lin, Y. W., & Truong, D. (2019). Diffuse Lewy body disease. Journal of the Neurological Sciences, 399, 144-150.

Meng, Y. H., Wang, P. P., Song, Y. X., & Wang, J. H. (2019). Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta analysis. Experimental and therapeutic medicine, 17(3), 1611-1624.

Masuda, M., Utsumi, H., Tanaka, S., Maeno, A., Yamamoto, M., Sugiyama, K., ... & Aizawa, H. (2018). Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients. Clinical Neuropharmacology, 41(5), 164-170.

Shoja Shafti, S., & Azizi Khoei, A. (2016). Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Therapeutic Advances in Psychopharmacology, 6(5), 308-316.

Ahmad, J., Hasan, M. J., Anam, A. M., & Barua, D. K. (2019). Donepezil: an unusual therapy for acute diphenhydramine overdose. BMJ Case Reports CP, 12(3), e226836.

Østergaard, D., Engbaek, J., & Viby-Mogensen, J. (1989). Adverse reactions and interactions of the neuromuscular blocking drugs. Medical Toxicology and Adverse Drug Experience, 4, 351-368.

Oliveira, C., Bagetta, D., Cagide, F., Teixeira, J., Amorim, R., Silva, T., ... & Borges, F. (2019). Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. European journal of medicinal chemistry, 174, 116-129.

Wang, P., Li, H., Hassan, M. M., Guo, Z., Zhang, Z. Z., & Chen, Q. (2019). Fabricating an acetylcholinesterase modulated UCNPs-Cu2+ fluorescence biosensor for ultrasensitive detection of organophosphorus pesticides-diazinon in food. Journal of agricultural and food chemistry, 67(14), 4071-4079.


Refbacks

  • There are currently no refbacks.